New blood test aims to catch ovarian cancer sooner

NCT ID NCT07593833

Not yet recruiting Diagnosis Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test a new blood test that looks for DNA changes to detect ovarian cancer, especially in early stages. Researchers will compare test results from 1,000 women with and without ovarian cancer to see how accurate it is. If it works well, it could lead to a simple screening tool for earlier diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Blood-based cfDNA methylation test
What this could lead to: If successful, this blood test could help detect ovarian cancer earlier, potentially improving treatment outcomes and survival rates.
What could go wrong: This is an early validation study, not yet recruiting. The test may not be accurate enough for widespread use, and results need confirmation in larger, diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY DETECTION OF CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease ovarian cancer ovarian neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EARLY DETECTION OF CANCER OVARIAN CANCER OVARIAN NEOPLASMS

Contacts and locations

Locations

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.